The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: A retrospective chart review involving up to 8 years of follow-up

Clinical Therapeutics

Volumn 28, Issue 2, 2006, Pages 243-250

  Nichols, Gregory A ^a   Koro, Carol E ^b   Chan, Wiley ^a,c   Bowlin, Steven J ^b   Sprecher, Dennis L ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

CVD; fibrates; HDL C

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OBESITY; POPULATION; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

AGE FACTORS; ANTILIPEMIC AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; COHORT STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORTHWESTERN UNITED STATES; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; SMOKING; TRIGLYCERIDES;

EID: 33646487146     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.02.003     Document Type: Review

References (16)

1. Kannel W. High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52 (1983) 9B-12B
2. Gordon T., Castelli W., Hjortland M., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62 (1977) 707-714
3. Goldbourt U., and Medalie J. High density lipoprotein cholesterol and incidence of coronary heart disease-the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 109 (1979) 296-308
4. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of athero-sclerotic coronary artery disease (the PROCAM experience) Prospective Cardiovascular Munster study. Am J Cardiol. 70 (1992) 733-737
5. [published correction appears in Circulation. 1998;97:1995]. Jeppesen J., Hein H., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 97 (1998) 1029-1036
6. for the Department of Veterans Affairs HDL Intervention Trial Study Group. Rubins H., Robins S., Collins D., et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol. 75 (1995) 1196-1201
7. Manninen V., Elo M., Frick M., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
8. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Rubins H., Robins S., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341 (1999) 410-418
9. Assmann G., and Schulte H. Role of triglycerides in coronary artery disease: Lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol. 70 (1992) 10H-13H
10. for the VA-HIT Study Group, Veterans Affairs High-Density Lipoprotein Intervention Trial. Robins S., Collins D., Wittes J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 285 (2001) 1585-1591
11. Stokes M., Davis C., and Koch G. Categorical Data Analysis Using the SAS System (2000), SAS Institute Inc, Cary, NC
12. [published correction appears in Lancet. 2001;357:1890]. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 357 (2001) 905-910
13. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
14. Castelli W., Garrison R., Wilson P., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
15. [published correction appears in JAMA. 2005;294:182]. Gregg E., Cheng Y., Cadwell B., et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 293 (2005) 1868-1874
16. Despres J., Lemieux I., and Robins S. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 64 (2004) 2177-2198